Idecabtagene vicleucel (ide-cel) is a B-cell maturation antigen–directed chimeric antigen receptor (CAR) T-cell therapy that has demonstrated clinical activity in RRMM. It also yielded the expected CAR T-cell toxic effects in these patients.
Per the results of the KarMMa trial, ide-cel mediated responses in most heavily pretreated patients with RRMM; MRD-negative status was attained by 26% of those administered treatment.
Notably, patients with diverse patient characteristics were included in the study (n=100). Patients were aged 33-78 years (median age: 62 years), and 37% harbored high-risk cytogenics. Furthermore, 36% of patients exhibited extramedullary plasmacytoma.
In a real-world study, U.S. researchers found that in 159 leukapheresed patients, ide-cel was as safe and effective as in the KarMMa trial. Moreover, 75% of infused patients would not have been eligible for participation in the KarMMA clinical trial due to comorbidities at the time of leukapheresis.
Which patient characteristics guide your clinical decisions in the treatment of RRMM?
-
Jean Yared, UMD MEDICAL CENTER2yrI look at the treatment history, exposure to Imids, PIs, mAbs, BCMA-targeted agents, tolerance of prior treatments, cytogenetic profile comorbidities, PS, and availability of well-designed clinical trial before making a Show More
-
Greg Guzley, METHODIST HOSPITAL2yrIn addition to the above mentioned issues of performance status, prior therapy status, responsive vs refractory to last line of therapy, and patient preference, the limited number of CAR-t centers Show More
